Retatrutide is supplied strictly as a laboratory research material. It is not approved, intended or authorised for human consumption or any therapeutic use. This article summarises published research for qualified scientists and is not medical advice.
One molecule, three receptors
Most of the metabolic drugs you've heard of hit a single target. Semaglutide is a GLP-1 receptor agonist. Tirzepatide adds a second — it's a dual GIP/GLP-1 agonist. Retatrutide (Eli Lilly's LY3437943) goes one further: it's a triple agonist that engages the receptors for GIP, GLP-1 and glucagon in a single peptide. If you want the ground-level primer first, our explainer on what Retatrutide is sets the scene; here we're digging into why the third receptor changes everything.
The instinct is to assume "more receptors = more of the same effect." That's not it. The reason Retatrutide is special is that its three targets don't just stack — they pull on two opposite ends of the energy-balance equation at once. To see why that matters, you have to look at what each receptor actually does.
What each receptor contributes
Body weight is, at its simplest, energy in minus energy out. Every incretin drug before Retatrutide worked almost entirely on the "in" side — eat less. Retatrutide's advantage is that it recruits a receptor that works on the "out" side too. Here's the division of labour:
- GLP-1 — the satiety and insulin arm. The GLP-1 receptor is the workhorse of the class. It slows gastric emptying, acts on appetite centres in the brain to reduce hunger, and drives glucose-dependent insulin secretion. This is the receptor doing most of the "I'm full" signalling and most of the blood-sugar control.
- GIP — the insulinotropic and adipose arm. GIP amplifies insulin release alongside GLP-1, but it also acts on adipose tissue, appearing to improve how fat is handled and stored. In combination it seems to smooth the metabolic side effects and add to the appetite effect — the reason dual GIP/GLP-1 agonists outperformed GLP-1 alone.
- Glucagon — the energy-expenditure and hepatic-lipid arm. This is the new ingredient. We tend to think of glucagon as the hormone that raises blood sugar, which sounds like the last thing a weight-loss compound would want. But glucagon-receptor activation also increases energy expenditure — the body burns more — and drives hepatic lipid mobilisation, stripping fat out of the liver. Paired with the glucose-lowering pull of GLP-1 and GIP, the unwanted sugar-raising effect is offset, leaving the fat-burning and calorie-burning benefits.
Retatrutide lowers energy intake and raises energy expenditure at the same time. Appetite goes down (GLP-1, GIP) while the body's calorie burn goes up and the liver offloads fat (glucagon). No monotherapy can do both — a GLP-1 drug can only push on the intake side. That simultaneous pull on both sides of the equation is the whole reason the effect is so large.
Why that combination is impossible with monotherapy
Give someone a pure glucagon agonist and you'd raise their blood sugar — a non-starter, especially in metabolic disease. Give them a pure GLP-1 agonist and you get excellent appetite suppression but nothing on the expenditure side. The elegance of a balanced triple agonist is that the GLP-1 and GIP components keep glucose in check, which licenses the glucagon component to do its fat- and energy-burning work safely. The three activities are co-dependent: none of them delivers the full effect alone, but tuned together in one peptide they unlock a mechanism single-target drugs simply cannot reach. Our deeper comparison of GLP-1 vs GIP vs glucagon agonists lays the three pharmacologies side by side.
What the trial data showed
The mechanism is elegant in theory — but the numbers are what turned Retatrutide into the most-discussed molecule in metabolic research. In the Phase 2 TRIUMPH-1 programme (published in the New England Journal of Medicine, 2023), participants on the highest 12 mg dose saw roughly 24.2% mean body-weight reduction at 48 weeks. For context, that is the largest effect reported for any compound in the incretin class to date.
The detail researchers find most striking isn't just the headline figure — it's that the curve hadn't plateaued when the trial ended. In most weight studies the loss flattens out well before the finish; here, participants were still trending downward at week 48, which implies the ceiling of the effect hadn't yet been reached. Our full Retatrutide research summary collects the dose-by-dose figures.
Beyond weight: the MASH and liver-fat angle
The glucagon arm has a second consequence that's driving a whole separate line of research. Because glucagon-receptor activation mobilises fat out of the liver, Retatrutide has been studied in MASH (metabolic dysfunction-associated steatohepatitis — the condition formerly called NASH). Phase 2 data reported substantial reductions in liver fat, with a large proportion of participants achieving near-complete resolution of hepatic steatosis. That's mechanistically consistent: the same receptor that raises energy expenditure is the one clearing lipid from the liver. It suggests Retatrutide's interest extends beyond body weight into fatty-liver disease — a field with few effective options.
A few practical notes
Two properties are worth knowing for research planning. Retatrutide has a long half-life of roughly six days, which supports once-weekly dosing schedules in the trials and means it reaches steady state slowly. And as with the rest of the class, it's supplied as a lyophilised powder for reconstitution. It remains an investigational compound — not an approved medicine, and supplied only as a research reagent for in vitro laboratory work.
The bottom line
What makes Retatrutide special isn't that it hits three receptors instead of one — it's which three, and what they do together. By adding the glucagon receptor to the GIP/GLP-1 backbone, it becomes the only incretin-class compound that pushes energy intake down and energy expenditure up simultaneously, while pulling fat out of the liver. That's the mechanism behind the ~24% Phase 2 result, behind the fact that it hadn't plateaued, and behind the MASH data. One molecule, doing two opposite jobs at once — that's the trick no monotherapy can copy.